Right. Short interest down 9.5%. Rett drug trial report meeting primary and secondary end points are just the beginning of 2-73 efficacy. Have to be crazy to be short this stock. MC is way low for successful CNS biotech drug. We all know that. imo . Happy Holidays T
More shorting the past few days but not nearly as much as the orchestrated short attack on 11/6, which covered by 12/15. Manipulation will continue to be in play as long as they can.